Latanoprost Plus NB-UVB Versus Each Alone in Non-segmental Vitiligo: Clinical and Laboratory Evaluation

Shaimaa Fawzy Abdel-rady Abdel-latif

Status and phase: Active, not recruiting; Phase 4

Conditions: Non-segmental Vitiligo

Treatments: Radiation: NB-UVB; Drug: Latanoprost

Study type: Interventional

Funder types: Other

Identifiers

NCT04811326

504/1/21

Details and patient eligibility

About

The aim of the study is to evaluate the efficacy of different lines of therapies on the TWEAK serum level in patients with non-segmental vitiligo.

Full description

the study is to evaluate the efficacy of NB-UVB, latanoprost, and combination of them on the TWEAK serum level in patients with non-segmental vitiligo.

Enrollment: 150 estimated patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients with non-segmental vitiligo of any age and gender.

Exclusion criteria

• History of vitiligo treatment with topical, systemic or biological agents prior to the study for at least 3 weeks.
• Pregnancy and lactation.
• Infections
• Patients with other autoimmune diseases.
• Patients with chronic diseases: cardiac diseases, hepatic disorders, hematologic disease, chronic renal failure or malignancies.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Factorial Assignment

Masking: Single Blind

---

150 participants in 4 patient groups

NB-UVB radiation

Active Comparator group

Description:

will expose to 2 sessions/week of NB-UVB radiation, for 3 months.

Treatment:

Radiation: NB-UVB

Latanoprost

Active Comparator group

Description:

latanoprost 0.005%, will be applied after microneedling, by using 1.5-2 mm needle length dermapen, of vitiligenous patches. The procedure will be repeated once weekly for 3 months (12 sessions).

Treatment:

Drug: Latanoprost

latanoprost + NB-UVB

Active Comparator group

Description:

(latanoprost + NB-UVB group): latanoprost 0.005%, will be applied after microneedling of vitiligenous patches in the same day of NB-UVB sessions in the same manner of group 2.

Treatment:

Drug: Latanoprost

Radiation: NB-UVB

healthy individuals

No Intervention group

Description:

healthy individuals as control group